XML 55 R28.htm IDEA: XBRL DOCUMENT

Note 1 - Nature of the Business (Tables)

12 Months Ended

Dec. 31, 2023

Notes Tables

Schedule of Subsidiaries [Table Text Block]

Name of company		Place of incorporation		Date of incorporation		Percentage of ownership by the Group		Principal activities
BeyondSpring Pharmaceuticals Inc. (“BeyondSpring US”)		Delaware, U.S.		June 18, 2013		100%		Clinical trial activities

BeyondSpring Ltd.		The British Virgin Islands (“BVI”)		December 3, 2014		100%		Holding company

BeyondSpring (HK) Limited (“BeyondSpring HK”)		Hong Kong		January 13, 2015		100%		Holding company

Wanchun Biotechnology Limited (“BVI Biotech”)		BVI		April 1, 2015		100%		Holding company

Wanchun Biotechnology (Dalian) Ltd. (“Wanchun Dalian”)		PRC		April 23, 2015		100%		Holding company

Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”)		PRC		May 6, 2015		57.97%		Clinical trial activities

Beijing Wanchun Pharmaceutical Technology Ltd. (“Beijing Wanchun”)		PRC		May 21, 2018		57.97%		Holding company

SEED Therapeutics Inc. (“SEED”)		BVI		June 25, 2019		55.05%		Pre-clinical development activities

SEED Technology Limited (“SEED Technology”)		BVI		December 9, 2019		57.97%		Holding company

SEED Therapeutics US, Inc. (“SEED US”)		Delaware, U.S.		November 25, 2020		55.05%		Pre-clinical development activities

Wanchun Hongji (Dalian) Pharmaceuticals Ltd. (“Wanchun Hongji”)		PRC		March 22, 2022		55.05%		Pre-clinical development activities